FDA issues guidance on generic versions of complex drugs
11-10-2018
FDA reveals further steps to encourage generic competition
03-01-2018
carmendorin / iStockphoto.com
The US Food and Drug Administration (FDA) has announced a new strategy for the use of “real-world evidence” (RWE) and “real-world data” (RWD) to improve its regulation of new drugs.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
FDA, real-world evidence, real-world data, Scott Gottlieb, 21st Century Cures Act, Framework for the FDA’s Real-World Evidence Program
